- Home
- VYNE vs NXTC Comparison
VYNE vs NXTC Comparison
Compare VYNE & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYNE
- NXTC
- Stock Information
- Founded
- VYNE 2003
- NXTC 2015
- Country
- VYNE United States
- NXTC United States
- Employees
- VYNE N/A
- NXTC N/A
- Industry
- VYNE Biotechnology: Pharmaceutical Preparations
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- VYNE Health Care
- NXTC Health Care
- Exchange
- VYNE Nasdaq
- NXTC Nasdaq
- Market Cap
- VYNE 16.0M
- NXTC 13.9M
- IPO Year
- VYNE 2018
- NXTC 2019
- Fundamental
- Price
- VYNE $1.45
- NXTC $0.44
- Analyst Decision
- VYNE Strong Buy
- NXTC Strong Buy
- Analyst Count
- VYNE 2
- NXTC 2
- Target Price
- VYNE $6.25
- NXTC $3.50
- AVG Volume (30 Days)
- VYNE 1.3M
- NXTC 357.7K
- Earning Date
- VYNE 08-13-2025
- NXTC 07-31-2025
- Dividend Yield
- VYNE N/A
- NXTC N/A
- EPS Growth
- VYNE N/A
- NXTC N/A
- EPS
- VYNE N/A
- NXTC N/A
- Revenue
- VYNE $605,000.00
- NXTC N/A
- Revenue This Year
- VYNE $42.51
- NXTC N/A
- Revenue Next Year
- VYNE N/A
- NXTC N/A
- P/E Ratio
- VYNE N/A
- NXTC N/A
- Revenue Growth
- VYNE 43.03
- NXTC N/A
- 52 Week Low
- VYNE $0.85
- NXTC $0.22
- 52 Week High
- VYNE $4.30
- NXTC $1.82
- Technical
- Relative Strength Index (RSI)
- VYNE 56.76
- NXTC 42.34
- Support Level
- VYNE $0.85
- NXTC $0.45
- Resistance Level
- VYNE $1.96
- NXTC $0.49
- Average True Range (ATR)
- VYNE 0.20
- NXTC 0.06
- MACD
- VYNE 0.07
- NXTC -0.01
- Stochastic Oscillator
- VYNE 51.80
- NXTC 4.72
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.